CureVac AG

CureVac AG

CureVac AG

Founded in 2000 as a spinoff from the University of Tbingen in Germany, CureVac is a technology leader in the development of drugs that are based on the molecule Messenger RNA (mRNA).
Founded
2000
Raised
$29.5M
Follow us
Featured on
Alexa global traffic share
Latest funding
$29,500,000
Venture capital (Series G) - 2016
Landeskreditbank Baden-Württemberg LBBW Asset Management Baden-Württembergische Versorgungsanstalt für Ärzte
Team Size
200+
Employees
Location
Headquarters
$29,500,000 Venture capital (Series G)
ENDPOINTS NEWS

CureVac grabs a $29.5M round to fuel its mRNA development efforts

Funding